Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01104870 · ClinicalTrials.gov registry record · Phase 2
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
A Phase 2 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01104870 is a Phase 2 study that has completed, run by United Therapeutics. The registered enrollment target is 50 participants.
The verdict
NCT01104870, a Phase 2 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a prospective, randomized, parallel group study to assess the hemodynamic effect of three different dose regimens of a sustained release (SR) tablet of UT-15C in patients with exercise-induced pulmonary hypertension (PH), as measured by the change in peak total pulmonary resistance index (TPRI) during exercise from Baseline to Week 12.
Interventions
- DRUG UT-15C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01104870
The ClinicalTrials.gov registry entry for NCT01104870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UT-15C is the first listed.
NCT01104870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01104870 about?
NCT01104870 is a clinical study titled "A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension". This is a prospective, randomized, parallel group study to assess the hemodynamic effect of three different dose regimens of a sustained release (SR) tablet of UT-15C in patients with exercise-induced pulmonary hypertension (PH), as measured by the change in peak total pulmonary resistance index (TP...
What is the current status of trial NCT01104870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2010-04. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01104870?
The interventions under investigation include: UT-15C (DRUG).
Who is sponsoring clinical trial NCT01104870?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.